Biologics to treat substance use disorders: Current status and new directions

References

• United Nations Office on Drugs and Crime (UNODC). World Drug Report 2015. Available at: http://www.unodc.org/wdr2015/
   Google Scholar
• National Survey on Drug Use and Health (NSDUH), 2014. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality. http://doi.org/10.3886/ICPSR36361.v1
   Google Scholar
• CDC. Wide-ranging OnLine Data for Epidemiologic Research (WONDER); 2014. Available at: http://wonder.cdc.gov/
   Google Scholar
• U.S. Department of Justice, Drug Enforcement Administration. National Drug Threat Assessment Summary, 2015. Available at: https://www.dea.gov/docs/2015%20NDTA%20Report.pdf
   Google Scholar
• Dodrill CL, Helmer DA, Kosten TR. Prescription pain medication dependence. Am J Psychiatry 2011; 168(5):466-71; PMID:21536702; http://dx.doi.org/10.1176/appi.ajp.2010.10020260
   PubMed Web of Science ®Google Scholar
• Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction 2014; 109(9):1414-25; PMID:24995905; http://dx.doi.org/10.1111/add.12633
   PubMed Web of Science ®Google Scholar
• Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 2009; 10(11):1727-40; PMID:19538000; http://dx.doi.org/10.1517/14656560903037168
   PubMed Web of Science ®Google Scholar
• Skolnick P, Volkow ND. Addiction therapeutics: obstacles and opportunities. Biol Psychiatry 2012; 72(11):890-1; PMID:23121867; http://dx.doi.org/10.1016/j.biopsych.2012.08.004
   PubMed Web of Science ®Google Scholar
• Narasimhan D, Woods JH, Sunahara RK. Bacterial cocaine esterase: a protein-based therapy for cocaine overdose and addiction. Future Med Chem 2012; 4(2):137-50; PMID:22300094; http://dx.doi.org/10.4155/fmc.11.194
   PubMed Web of Science ®Google Scholar
• Pentel PR, LeSage MG. New directions in nicotine vaccine design and use. Adv Pharmacol 2014; 69:553-80; PMID:24484987; http://dx.doi.org/10.1016/B978-0-12-420118-7.00014-7
   PubMedGoogle Scholar
• Stowe GN, Schlosburg JE, Vendruscolo LF, Edwards S, Misra KK, Schulteis G, Zakhari JS, Koob GF, Janda KD. Developing a vaccine against multiple psychoactive targets: a case study of heroin. CNS Neurol Disord Drug Targets 2011; 10(8):865-75; PMID:22229311; http://dx.doi.org/10.2174/187152711799219316
   PubMed Web of Science ®Google Scholar
• Brimijoin S. Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users. CNS Neurol Disord Drug Targets 2011; 10(8):880-91; PMID:22229308; http://dx.doi.org/10.2174/187152711799219398
   PubMed Web of Science ®Google Scholar
• Brimijoin S, Gao Y. Cocaine hydrolase gene therapy for cocaine abuse. Future Med Chem 2012; 4(2):151-62; PMID:22300095; http://dx.doi.org/10.4155/fmc.11.183
   PubMed Web of Science ®Google Scholar
• Brimijoin S, Shen X, Orson F, Kosten T. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines 2013; 12(3):323-32; PMID:23496671; http://dx.doi.org/10.1586/erv.13.1
   PubMed Web of Science ®Google Scholar
• Orson FM, Wang R, Brimijoin S, Kinsey BM, Singh RA, Ramakrishnan M, Wang HY, Kosten TR. The future potential for cocaine vaccines. Expert Opin Biol Ther 2014; 14(9):1271-83; PMID:24835496; http://dx.doi.org/10.1517/14712598.2014.920319
   PubMed Web of Science ®Google Scholar
• Peterson EC, Gentry WB, Owens SM. Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications. Adv Pharmacol 2014; 69:107-27; PMID:24484976; http://dx.doi.org/10.1016/B978-0-12-420118-7.00003-2
   PubMedGoogle Scholar
• Skolnick P. Biologic approaches to treat substance-use disorders. Trends Pharmacol Sci 2015; 36(10):628-35; PMID:26435208; http://dx.doi.org/10.1016/j.tips.2015.07.002
   PubMed Web of Science ®Google Scholar
• Zheng F, Zhan CG. Structure-and-mechanism-based design and discovery of therapeutics for cocaine overdose and addiction. Org Biomol Chem 2008; 6(5):836-43; PMID:18292872; http://dx.doi.org/10.1039/B716268E
   PubMed Web of Science ®Google Scholar
• Montoya ID, editor. Biologics to treat substance use disorders: vaccines, monoclonal antibodies, and enzymes. Cham, Switzerland: Springer; 2016
   Google Scholar
• Shen XY, Orson FM, Kosten TR. Vaccines against drug abuse. Clin Pharmacol Ther 2012; 91(1):60-70; PMID:22130115; http://dx.doi.org/10.1038/clpt.2011.281
   PubMed Web of Science ®Google Scholar
• Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, Bangala Y, Guessous I, Muller P, Willers J, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008; 3(6):e2547; PMID:18575629
   PubMed Web of Science ®Google Scholar
• Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA, Tashkin DP, Reus VI, Akhavain RC, Fahim RE, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 2011; 89(3):392-9; PMID:21270788
   PubMed Web of Science ®Google Scholar
• Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, Kosten TR. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 2009; 66(10):1116-23; PMID:19805702
   PubMed Web of Science ®Google Scholar
• Fahim RE, Kessler PD, Kalnik MW. Therapeutic vaccines against tobacco addiction. Expert Rev Vaccines 2013; 12(3):333-42; PMID:23496672
   PubMed Web of Science ®Google Scholar
• McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol 2005; 23:487-513; PMID:15771579
   PubMed Web of Science ®Google Scholar
• McHeyzer-Williams M, Okitsu S, Wang N, McHeyzer-Williams L. Molecular programming of B cell memory. Nat Rev Immunol 2012; 12(1):24-34
   Web of Science ®Google Scholar
• Shulman Z, Gitlin AD, Targ S, Jankovic M, Pasqual G, Nussenzweig MC, Victora GD. T follicular helper cell dynamics in germinal centers. Science 2013; 341(6146):673-7; PMID:23887872
   PubMed Web of Science ®Google Scholar
• Tarlinton DM. Evolution in miniature: selection, survival and distribution of antigen reactive cells in the germinal centre. Immunol Cell Biol 2008; 86(2):133-8; PMID:18180800
   PubMed Web of Science ®Google Scholar
• Victora GD, Mesin L. Clonal and cellular dynamics in germinal centers. Curr Opin Immunol 2014; 28:90-6; PMID:24681449
   PubMed Web of Science ®Google Scholar
• Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol 2012; 30:429-57; PMID:22224772
   PubMed Web of Science ®Google Scholar
• Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011; 29:621-63; PMID:21314428
   PubMed Web of Science ®Google Scholar
• Crotty S. A brief history of T cell help to B cells. Nat Rev Immunol 2015; 15(3):185-9; PMID:25677493
   PubMed Web of Science ®Google Scholar
• Pape KA, Taylor JJ, Maul RW, Gearhart PJ, Jenkins MK. Different B cell populations mediate early and late memory during an endogenous immune response. Science 2011; 331(6021):1203-7; PMID:21310965
   PubMed Web of Science ®Google Scholar
• Moon JJ, Chu HH, Hataye J, Pagan AJ, Pepper M, McLachlan JB, Zell T, Jenkins MK. Tracking epitope-specific T cells. Nat Protoc 2009; 4(4):565-81; PMID:19373228
   PubMed Web of Science ®Google Scholar
• Jenkins MK, Chu HH, McLachlan JB, Moon JJ. On the composition of the preimmune repertoire of T cells specific for Peptide-major histocompatibility complex ligands. Annu Rev Immunol 2010; 28:275-94; PMID:20307209
   PubMed Web of Science ®Google Scholar
• Jenkins MK, Moon JJ. The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude. J Immunol 2012; 188(9):4135-40; PMID:22517866; http://dx.doi.org/10.4049/jimmunol.1102661
   PubMed Web of Science ®Google Scholar
• Taylor JJ, Martinez RJ, Titcombe PJ, Barsness LO, Thomas SR, Zhang N, Katzman SD, Jenkins MK, Mueller DL. Deletion and anergy of polyclonal B cells specific for ubiquitous membrane-bound self-antigen. J Exp Med 2012; 209(11):2065-77; PMID:23071255; http://dx.doi.org/10.1084/jem.20112272
   PubMed Web of Science ®Google Scholar
• Taylor JJ, Pape KA, Steach HR, Jenkins MK. Humoral immunity. Apoptosis and antigen affinity limit effector cell differentiation of a single naive B cell. Science 2015; 347(6223):784-7; PMID:25636798; http://dx.doi.org/10.1126/science.aaa1342
   PubMed Web of Science ®Google Scholar
• Tubo NJ, Pagan AJ, Taylor JJ, Nelson RW, Linehan JL, Ertelt JM, Huseby ES, Way SS, Jenkins MK. Single naive CD4(+) T Cells from a diverse repertoire produce different effector cell types during infection. Cell 2013; 153(4):785-96; PMID:23663778; http://dx.doi.org/10.1016/j.cell.2013.04.007
   PubMed Web of Science ®Google Scholar
• Taylor JJ, Laudenbach M, Tucker AM, Jenkins MK, Pravetoni M. Hapten-specific naive B cells are biomarkers of vaccine efficacy against drugs of abuse. J Immunol Methods 2014; 405:74-86; PMID:24462800; http://dx.doi.org/10.1016/j.jim.2014.01.010
   PubMed Web of Science ®Google Scholar
• Laudenbach M, Tucker AM, Runyon SP, Carroll FI, Pravetoni M. The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence. Vaccine 2015; 33(46):6332-9; PMID:26409811; http://dx.doi.org/10.1016/j.vaccine.2015.09.015
   PubMed Web of Science ®Google Scholar
• Pravetoni M, Vervacke JS, Distefano MD, Tucker AM, Laudenbach M, Pentel PR. Effect of currently approved carriers and adjuvants on the pre-clinical efficacy of a conjugate vaccine against oxycodone in mice and rats. PLoS One 2014; 9(5):e96547; PMID:24797666; http://dx.doi.org/10.1371/journal.pone.0096547
   PubMedGoogle Scholar
• Laudenbach M, Baruffaldi F, Vervacke JS, Distefano MD, Titcombe PJ, Mueller DL, Tubo NJ, Griffith TS, Pravetoni M. The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse. J Immunol 2015; 194(12):5926-36; PMID:25972483; http://dx.doi.org/10.4049/jimmunol.1500385
   PubMed Web of Science ®Google Scholar
• Bremer PT, Janda KD. Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance. J Med Chem 2012; 55(23):10776-80; PMID:23134263; http://dx.doi.org/10.1021/jm301262z
   PubMed Web of Science ®Google Scholar
• Bremer PT, Schlosburg JE, Lively JM, Janda KD. Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy. Mol Pharm 2014; 11(3):1075-80; PMID:24517171; http://dx.doi.org/10.1021/mp400631w
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Pryde DC, Gervais DP, Stead DR, Zhang N, Benoit M, Robertson K, Kim IJ, Tharmanathan T, Merson JR, et al. Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. Int Immunopharmacol 2013; 16(1):50-6; PMID:23562759; http://dx.doi.org/10.1016/j.intimp.2013.03.021
   PubMed Web of Science ®Google Scholar
• Zheng H, Hu Y, Huang W, de Villiers S, Pentel P, Zhang J, Dorn H, Ehrich M, Zhang C. Negatively charged carbon nanohorn supported cationic liposome nanoparticles: A novel delivery vehicle for anti-nicotine vaccine. J Biomed Nanotechnol 2015; 11(12):2197-210; PMID:26510313; http://dx.doi.org/10.1166/jbn.2015.2156
   PubMed Web of Science ®Google Scholar
• Tubo NJ, Jenkins MK. TCR signal quantity and quality in CD4 T cell differentiation. Trends Immunol 2014; 35(12):591-6; PMID:25457838; http://dx.doi.org/10.1016/j.it.2014.09.008
   PubMed Web of Science ®Google Scholar
• Malherbe L, Mark L, Fazilleau N, McHeyzer-Williams LJ, McHeyzer-Williams MG. Vaccine adjuvants alter TCR-based selection thresholds. Immunity 2008; 28(5):698-709; PMID:18450485; http://dx.doi.org/10.1016/j.immuni.2008.03.014
   PubMed Web of Science ®Google Scholar
• van Panhuys N, Klauschen F, Germain RN. T-cell-receptor-dependent signal intensity dominantly controls CD4(+) T cell polarization in vivo. Immunity 2014; 41(1):63-74; PMID:24981853; http://dx.doi.org/10.1016/j.immuni.2014.06.003
   PubMed Web of Science ®Google Scholar
• Tubo NJ, Fife BT, Pagan AJ, Kotov DI, Goldberg MF, Jenkins MK. Most microbe-specific naive CD4(+) T cells produce memory cells during infection. Science 2016; 351(6272):511-4; PMID:26823430; http://dx.doi.org/10.1126/science.aad0483
   PubMed Web of Science ®Google Scholar
• Lofano G, Mancini F, Salvatore G, Cantisani R, Monaci E, Carrisi C, Tavarini S, Sammicheli C, Rossi Paccani S, Soldaini E, et al. Oil-in-water emulsion MF59 increases Germinal Center B cell differentiation and persistence in response to vaccination. J Immunol 2015; 195(4):1617-27; PMID:26170383; http://dx.doi.org/10.4049/jimmunol.1402604
   PubMed Web of Science ®Google Scholar
• Baumjohann D, Preite S, Reboldi A, Ronchi F, Ansel KM, Lanzavecchia A, Sallusto F. Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity 2013; 38(3):596-605; PMID:23499493; http://dx.doi.org/10.1016/j.immuni.2012.11.020
   PubMed Web of Science ®Google Scholar
• Chu HH, Moon JJ, Kruse AC, Pepper M, Jenkins MK. Negative selection and peptide chemistry determine the size of naive foreign peptide-MHC class II-specific CD4+ T cell populations. J Immunol 2010; 185(8):4705-13; PMID:20861357; http://dx.doi.org/10.4049/jimmunol.1002276
   PubMed Web of Science ®Google Scholar
• Chu HH, Moon JJ, Takada K, Pepper M, Molitor JA, Schacker TW, Hogquist KA, Jameson SC, Jenkins MK. Positive selection optimizes the number and function of MHCII-restricted CD4+ T cell clones in the naive polyclonal repertoire. Proc Natl Acad Sci U S A 2009; 106(27):11241-5; PMID:19541603; http://dx.doi.org/10.1073/pnas.0902015106
   PubMed Web of Science ®Google Scholar
• Moon JJ, Chu HH, Pepper M, McSorley SJ, Jameson SC, Kedl RM, Jenkins MK. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 2007; 27(2):203-13; PMID:17707129; http://dx.doi.org/10.1016/j.immuni.2007.07.007
   PubMed Web of Science ®Google Scholar
• Taylor JJ, Jenkins MK, Pape KA. Heterogeneity in the differentiation and function of memory B cells. Trends Immunol 2012; 33(12):590-7; PMID:22920843; http://dx.doi.org/10.1016/j.it.2012.07.005
   PubMed Web of Science ®Google Scholar
• Taylor JJ, Pape KA, Jenkins MK. A germinal center-independent pathway generates unswitched memory B cells early in the primary response. J Exp Med 2012; 209(3):597-06; PMID:22370719; http://dx.doi.org/10.1084/jem.20111696
   PubMed Web of Science ®Google Scholar
• Becattini S, Latorre D, Mele F, Foglierini M, De Gregorio C, Cassotta A, Fernandez B, Kelderman S, Schumacher TN, Corti D, et al. T cell immunity. Functional heterogeneity of human memory CD4(+) T cell clones primed by pathogens or vaccines. Science 2015; 347(6220):400-6; PMID:25477212; http://dx.doi.org/10.1126/science.1260668
   PubMed Web of Science ®Google Scholar
• Geiger R, Duhen T, Lanzavecchia A, Sallusto F. Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J Exp Med 2009; 206(7):1525-34; PMID:19564353; http://dx.doi.org/10.1084/jem.20090504
   PubMed Web of Science ®Google Scholar
• Fraser CC, Altreuter DH, Ilyinskii P, Pittet L, LaMothe RA, Keegan M, Johnston L, Kishimoto TK. Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates. Vaccine 2014; 32(24):2896-903; PMID:24583006; http://dx.doi.org/10.1016/j.vaccine.2014.02.024
   PubMed Web of Science ®Google Scholar
• Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, Ahmed R, Bhan MK, Plotkin SA. Accelerating next-generation vaccine development for global disease prevention. Science 2013; 340(6136):1232910; PMID:23723240; http://dx.doi.org/10.1126/science.1232910
   PubMed Web of Science ®Google Scholar
• Georgiou G, Ippolito GC, Beausang J, Busse CE, Wardemann H, Quake SR. The promise and challenge of high-throughput sequencing of the antibody repertoire. Nat Biotechnol 2014; 32(2):158-68; PMID:24441474; http://dx.doi.org/10.1038/nbt.2782
   PubMed Web of Science ®Google Scholar
• Tsang JS, Schwartzberg PL, Kotliarov Y, Biancotto A, Xie Z, Germain RN, Wang E, Olnes MJ, Narayanan M, Golding H, et al. Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell 2014; 157(2):499-513; PMID:24725414; http://dx.doi.org/10.1016/j.cell.2014.03.031
   PubMed Web of Science ®Google Scholar
• Janda KD, Treweek JB. Vaccines targeting drugs of abuse: is the glass half-empty or half-full? Nat Rev Immunol 2011; 12(1):67-72; PMID:22173478
   PubMed Web of Science ®Google Scholar
• Kinsey B. Vaccines against drugs of abuse: where are we now? Ther Adv Vaccines 2014; 2(4):106-17; PMID:24982760; http://dx.doi.org/10.1177/2051013614537818
   PubMedGoogle Scholar
• Alving CR, Matyas GR, Torres O, Jalah R, Beck Z. Adjuvants for vaccines to drugs of abuse and addiction. Vaccine 2014; 32(42):5382-9; PMID:25111169; http://dx.doi.org/10.1016/j.vaccine.2014.07.085
   PubMed Web of Science ®Google Scholar
• Kosten T, Domingo C, Orson F, Kinsey B. Vaccines against stimulants: cocaine and MA. Br J Clin Pharmacol 2014; 77(2):368-74; PMID:23509915; http://dx.doi.org/10.1111/bcp.12115
   PubMed Web of Science ®Google Scholar
• Cai X, Whitfield T, Moreno AY, Grant Y, Hixon MS, Koob GF, Janda KD. Probing the effects of hapten stability on cocaine vaccine immunogenicity. Mol Pharm 2013; 10(11):4176-84; PMID:23927436; http://dx.doi.org/10.1021/mp400214w
   PubMed Web of Science ®Google Scholar
• Lockner JW, Lively JM, Collins KC, Vendruscolo JC, Azar MR, Janda KD. A conjugate vaccine using enantiopure hapten imparts superior nicotine-binding capacity. J Med Chem 2015; 58(2):1005-11; PMID:25493909; http://dx.doi.org/10.1021/jm501625j
   PubMed Web of Science ®Google Scholar
• Cai X, Tsuchikama K, Janda KD. Modulating cocaine vaccine potency through hapten fluorination. J Am Chem Soc 2013; 135(8):2971-4; PMID:23398531; http://dx.doi.org/10.1021/ja400356g
   PubMed Web of Science ®Google Scholar
• Collins KC, Janda KD. Investigating hapten clustering as a strategy to enhance vaccines against drugs of abuse. Bioconjug Chem 2014; 25(3):593-600; PMID:24521489; http://dx.doi.org/10.1021/bc500016k
   PubMed Web of Science ®Google Scholar
• Moreno AY, Mayorov AV, Janda KD. Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc 2011; 133(17):6587-95; PMID:21473576; http://dx.doi.org/10.1021/ja108807j
   PubMed Web of Science ®Google Scholar
• Pravetoni M, Le Naour M, Harmon T, Tucker A, Portoghese PS, Pentel PR. An oxycodone conjugate vaccine elicits oxycodone-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. J Pharmacol Exp Ther 2012; 341(1):225-32; PMID:22262924; http://dx.doi.org/10.1124/jpet.111.189506
   PubMed Web of Science ®Google Scholar
• Pravetoni M, Le Naour M, Tucker AM, Harmon TM, Hawley TM, Portoghese PS, Pentel PR. Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. J Med Chem 2013; 56(3):915-23; PMID:23249238; http://dx.doi.org/10.1021/jm3013745
   PubMed Web of Science ®Google Scholar
• Pravetoni M, Pentel PR, Potter DN, Chartoff EH, Tally L, LeSage MG. Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats. PLoS One 2014; 9(7):e101807; PMID:25025380; http://dx.doi.org/10.1371/journal.pone.0101807
   PubMed Web of Science ®Google Scholar
• Raleigh MD, Pentel PR, LeSage MG. Pharmacokinetic correlates of the effects of a heroin vaccine on heroin self-administration in rats. PLoS One 2014; 9(12):e115696; PMID:25536404; http://dx.doi.org/10.1371/journal.pone.0115696
   PubMed Web of Science ®Google Scholar
• Raleigh MD, Pravetoni M, Harris AC, Birnbaum AK, Pentel PR. Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats. J Pharmacol Exp Ther 2013; 344(2):397-406; PMID:23220743; http://dx.doi.org/10.1124/jpet.112.201194
   PubMed Web of Science ®Google Scholar
• Anton B, Leff P. A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 2006; 24(16):3232-40; PMID:16494974; http://dx.doi.org/10.1016/j.vaccine.2006.01.047
   PubMed Web of Science ®Google Scholar
• Li QQ, Luo YX, Sun CY, Xue YX, Zhu WL, Shi HS, Zhai HF, Shi J, Lu L. A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats. J Neurochem 2011; 119(6):1271-81; PMID:21951213; http://dx.doi.org/10.1111/j.1471-4159.2011.07502.x
   PubMed Web of Science ®Google Scholar
• Kosten TA, Shen XY, O'Malley PW, Kinsey BM, Lykissa ED, Orson FM, Kosten TR. A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats. Prog Neuropsychopharmacol Biol Psychiatry 2013; 45:223-9; PMID:23739535; http://dx.doi.org/10.1016/j.pnpbp.2013.05.012
   PubMed Web of Science ®Google Scholar
• Li F, Cheng K, Antoline JF, Iyer MR, Matyas GR, Torres OB, Jalah R, Beck Z, Alving CR, Parrish DA, et al. Synthesis and immunological effects of heroin vaccines. Org Biomol Chem 2014; 12(37):7211-32; PMID:24995943; http://dx.doi.org/10.1039/C4OB01053A
   PubMed Web of Science ®Google Scholar
• Schlosburg JE, Vendruscolo LF, Bremer PT, Lockner JW, Wade CL, Nunes AA, Stowe GN, Edwards S, Janda KD, Koob GF. Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci U S A 2013; 110(22):9036-41; PMID:23650354; http://dx.doi.org/10.1073/pnas.1219159110
   PubMed Web of Science ®Google Scholar
• Stowe GN, Vendruscolo LF, Edwards S, Schlosburg JE, Misra KK, Schulteis G, Mayorov AV, Zakhari JS, Koob GF, Janda KD. A vaccine strategy that induces protective immunity against heroin. J Med Chem 2011; 54(14):5195-204; PMID:21692508; http://dx.doi.org/10.1021/jm200461m
   PubMed Web of Science ®Google Scholar
• Carroll FI, Blough BE, Pidaparthi RR, Abraham P, Gong PK, Deng L, Huang X, Gunnell M, Lay JO, Jr, Peterson EC, et al. Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. J Med Chem 2011; 54(14):5221-8; PMID:21682289; http://dx.doi.org/10.1021/jm2004943
   PubMed Web of Science ®Google Scholar
• Pravetoni M, Keyler DE, Pidaparthi RR, Carroll FI, Runyon SP, Murtaugh MP, Earley CA, Pentel PR. Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol 2012; 83(4):543-50; PMID:22100986; http://dx.doi.org/10.1016/j.bcp.2011.11.004
   PubMed Web of Science ®Google Scholar
• Pryde DC, Jones LH, Gervais DP, Stead DR, Blakemore DC, Selby MD, Brown AD, Coe JW, Badland M, Beal DM, et al. Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice. PLoS One 2013; 8(10):e76557; PMID:24098532; http://dx.doi.org/10.1371/journal.pone.0076557
   PubMed Web of Science ®Google Scholar
• Jalah R, Torres OB, Mayorov AV, Li F, Antoline JF, Jacobson AE, Rice KC, Deschamps JR, Beck Z, Alving CR, et al. Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers. Bioconjug Chem 2015; 26(6):1041-53; PMID:25970207; http://dx.doi.org/10.1021/acs.bioconjchem.5b00085
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Thorn J, Mehelic PR, Kolhe P, Bhattacharya K, Finneman JI, Stead DR, Piatchek MB, Zhang N, Chikh G, et al. Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates. Int Immunopharmacol 2015; 25(2):518-27; PMID:25737198; http://dx.doi.org/10.1016/j.intimp.2015.02.030
   PubMed Web of Science ®Google Scholar
• Matyas GR, Mayorov AV, Rice KC, Jacobson AE, Cheng K, Iyer MR, Li F, Beck Z, Janda KD, Alving CR. Liposomes containing monophosphoryl lipid A: A potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine 2013; 31(26):2804-10; PMID:23624097; http://dx.doi.org/10.1016/j.vaccine.2013.04.027
   PubMed Web of Science ®Google Scholar
• Sanderson SD, Cheruku SR, Padmanilayam MP, Vennerstrom JL, Thiele GM, Palmatier MI, Bevins RA. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int Immunopharmacol 2003; 3(1):137-46; PMID:12538044; http://dx.doi.org/10.1016/S1567-5769(02)00260-6
   PubMed Web of Science ®Google Scholar
• Duryee MJ, Bevins RA, Reichel CM, Murray JE, Dong Y, Thiele GM, Sanderson SD. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine 2009; 27(22):2981-8; PMID:19428909; http://dx.doi.org/10.1016/j.vaccine.2009.02.105
   PubMed Web of Science ®Google Scholar
• Pravetoni M, Raleigh MD, Le Naour M, Tucker AM, Harmon TM, Jones JM, Birnbaum AK, Portoghese PS, Pentel PR. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine 2012; 30(31):4617-24; PMID:22583811; http://dx.doi.org/10.1016/j.vaccine.2012.04.101
   PubMed Web of Science ®Google Scholar
• Haile CN, Kosten TA, Shen XY, O'Malley PW, Winoske KJ, Kinsey BM, Wu Y, Huang Z, Lykissa ED, Naidu N, et al. Altered methamphetamine place conditioning in mice vaccinated with a succinyl-methamphetamine-tetanus-toxoid vaccine. Am J Addict 2015; 24(8):748-55; PMID:26584468; http://dx.doi.org/10.1111/ajad.12307
   PubMed Web of Science ®Google Scholar
• Miller ML, Aarde SM, Moreno AY, Creehan KM, Janda KD, Taffe MA. Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats. Drug Alcohol Depend 2015; 153:29-36; PMID:26118833; http://dx.doi.org/10.1016/j.drugalcdep.2015.06.014
   PubMed Web of Science ®Google Scholar
• Miller ML, Moreno AY, Aarde SM, Creehan KM, Vandewater SA, Vaillancourt BD, Wright MJ, Jr, Janda KD, Taffe MA. A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats. Biol Psychiatry 2013; 73(8):721-8; PMID:23098894; http://dx.doi.org/10.1016/j.biopsych.2012.09.010
   PubMed Web of Science ®Google Scholar
• Ruedi-Bettschen D, Wood SL, Gunnell MG, West CM, Pidaparthi RR, Carroll FI, Blough BE, Owens SM. Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food. Vaccine 2013; 31(41):4596-602; PMID:23906885; http://dx.doi.org/10.1016/j.vaccine.2013.07.038
   PubMed Web of Science ®Google Scholar
• Shen XY, Kosten TA, Lopez AY, Kinsey BM, Kosten TR, Orson FM. A vaccine against methamphetamine attenuates its behavioral effects in mice. Drug Alcohol Depend 2013; 129(1-2):41-8; PMID:23022610; http://dx.doi.org/10.1016/j.drugalcdep.2012.09.007
   PubMed Web of Science ®Google Scholar
• Broker M, Costantino P, DeTora L, McIntosh ED, Rappuoli R. Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals 2011; 39(4):195-204; PMID:21715186; http://dx.doi.org/10.1016/j.biologicals.2011.05.004
   PubMed Web of Science ®Google Scholar
• Lockner JW, Eubanks LM, Choi JL, Lively JM, Schlosburg JE, Collins KC, Globisch D, Rosenfeld-Gunn RJ, Wilson IA, Janda KD. Flagellin as carrier and adjuvant in cocaine vaccine development. Mol Pharm 2015; 12(2):653-62; PMID:25531528; http://dx.doi.org/10.1021/mp500520r
   PubMed Web of Science ®Google Scholar
• Miller KD, Roque R, Clegg CH. Novel anti-nicotine vaccine using a trimeric coiled-coil hapten carrier. PLoS One 2014; 9(12):e114366; PMID:25494044; http://dx.doi.org/10.1371/journal.pone.0114366
   PubMed Web of Science ®Google Scholar
• Maoz A, Hicks MJ, Vallabhjosula S, Synan M, Kothari PJ, Dyke JP, Ballon DJ, Kaminsky SM, De BP, Rosenberg JB, et al. Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter. Neuropsychopharmacol 2013; 38(11):2170-8; http://dx.doi.org/10.1038/npp.2013.114
   PubMed Web of Science ®Google Scholar
• Rosenberg J, De B, Hicks M, Janda K, Kaminsky S, Worgall S, Crystal R. Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based anti-nicotine vaccine. Hum Gene Ther 2013; 24(6):595-603; PMID:23611296; http://dx.doi.org/10.1089/hum.2012.245
   PubMed Web of Science ®Google Scholar
• Hicks MJ, Kaminsky SM, De BP, Rosenberg JB, Evans SM, Foltin RW, Andrenyak DM, Moody DE, Koob GF, Janda KD, et al. Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anticocaine vaccine. Hum Gene Ther Clin Dev 2014; 25(1):40-9; PMID:24649839; http://dx.doi.org/10.1089/humc.2013.231
   PubMed Web of Science ®Google Scholar
• Koob G, Hicks MJ, Wee S, Rosenberg JB, De BP, Kaminsky SM, Moreno A, Janda KD, Crystal RG. Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus. CNS Neurol Disord Drug Targets 2011; 10(8):899-904; PMID:22229312; http://dx.doi.org/10.2174/187152711799219334
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Fox CB. New generation adjuvants–from empiricism to rational design. Vaccine 2015; 33(Suppl 2):B14-20; http://dx.doi.org/10.1016/j.vaccine.2015.01.088
   PubMed Web of Science ®Google Scholar
• Mastelic Gavillet B, Eberhardt CS, Auderset F, Castellino F, Seubert A, Tregoning JS, Lambert PH, de Gregorio E, Del Giudice G, Siegrist CA. MF59 mediates its B cell adjuvanticity by promoting T Follicular helper cells and thus germinal center responses in adult and early life. J Immunol 2015; 194(10):4836-45; PMID:25870238; http://dx.doi.org/10.4049/jimmunol.1402071
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Thorn J, Gervais DP, Stead DR, Zhang N, Benoit M, Cartier J, Kim IJ, Bhattacharya K, Finneman JI, et al. Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates. Int Immunopharmacol 2015; 29(2):663-71; PMID:26404190; http://dx.doi.org/10.1016/j.intimp.2015.09.012
   PubMed Web of Science ®Google Scholar
• Bremer PT, Kimishima A, Schlosburg JE, Zhou B, Collins KC, Janda KD. Combatting synthetic designer opioids: A conjugate vaccine ablates lethal doses of fentanyl class drugs. Angew Chem Int Ed Engl 2016; 55(11):3772-5; PMID:26879590; http://dx.doi.org/10.1002/anie.201511654
   PubMed Web of Science ®Google Scholar
• Chen X, Kim P, Farinelli B, Doukas A, Yun SH, Gelfand JA, Anderson RR, Wu MX. A novel laser vaccine adjuvant increases the motility of antigen presenting cells. PLoS One 2010; 5(10):e13776; PMID:21048884; http://dx.doi.org/10.1371/journal.pone.0013776
   PubMed Web of Science ®Google Scholar
• Chen X, Pravetoni M, Bhayana B, Pentel PR, Wu MX. High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine 2012; 31(1):159-64; PMID:23123021; http://dx.doi.org/10.1016/j.vaccine.2012.10.069
   PubMed Web of Science ®Google Scholar
• Irvine DJ, Hanson MC, Rakhra K, Tokatlian T. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev 2015; 115(19):11109-46; PMID:26154342; http://dx.doi.org/10.1021/acs.chemrev.5b00109
   PubMed Web of Science ®Google Scholar
• Moon JJ, Huang B, Irvine DJ. Engineering nano- and microparticles to tune immunity. Adv Mater 2012; 24(28):3724-46; PMID:22641380; http://dx.doi.org/10.1002/adma.201200446
   PubMed Web of Science ®Google Scholar
• Jain S, O'Hagan DT, Singh M. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev Vaccines 2011; 10(12):1731-42; PMID:22085176; http://dx.doi.org/10.1586/erv.11.126
   PubMed Web of Science ®Google Scholar
• Braun M, Jandus C, Maurer P, Hammann-Haenni A, Schwarz K, Bachmann MF, Speiser DE, Romero P. Virus-like particles induce robust human T-helper cell responses. Eur J Immunol 2012; 42(2):330-40; PMID:22057679; http://dx.doi.org/10.1002/eji.201142064
   PubMed Web of Science ®Google Scholar
• Zabel F, Mohanan D, Bessa J, Link A, Fettelschoss A, Saudan P, Kundig TM, Bachmann MF. Viral particles drive rapid differentiation of memory B cells into secondary plasma cells producing increased levels of antibodies. J Immunol 2014; 192(12):5499-508; PMID:24821969; http://dx.doi.org/10.4049/jimmunol.1400065
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmuller B, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365(20):1863-75; PMID:22007715; http://dx.doi.org/10.1056/NEJMoa1102287
   PubMed Web of Science ®Google Scholar
• RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmuller B, Issifou S, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367(24):2284-95; PMID:23136909; http://dx.doi.org/10.1056/NEJMoa1208394
   PubMed Web of Science ®Google Scholar
• Collins KC, Schlosburg JE, Lockner JW, Bremer PT, Ellis BA, Janda KD. Lipid tucaresol as an adjuvant for methamphetamine vaccine development. Chem Commun (Camb) 2014; 50(31):4079-81; PMID:24615284; http://dx.doi.org/10.1039/c4cc00682h
   PubMed Web of Science ®Google Scholar
• Lockner JW, Ho SO, McCague KC, Chiang SM, Do TQ, Fujii G, Janda KD. Enhancing nicotine vaccine immunogenicity with liposomes. Bioorg Med Chem Lett 2013; 23(4):975-8; PMID:23313243; http://dx.doi.org/10.1016/j.bmcl.2012.12.048
   PubMed Web of Science ®Google Scholar
• Hu Y, Zheng H, Huang W, Zhang C. A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle. Hum Vaccin Immunother 2014; 10(1):64-72; http://dx.doi.org/10.4161/hv.26635
   Web of Science ®Google Scholar
• Desai RI, Bergman J. Effects of the nanoparticle-based vaccine, SEL-068, on nicotine discrimination in squirrel monkeys. Neuropsychopharmacol 2015; 40(9):2207-16; http://dx.doi.org/10.1038/npp.2015.64
   PubMed Web of Science ®Google Scholar
• Desai RI, Bergman J. Nicotine-targeting nano-vaccines for smoking cessation. Neuropsychopharmacol 2016; 41(1):377-8; http://dx.doi.org/10.1038/npp.2015.234
   PubMed Web of Science ®Google Scholar
• Ilyinskii PO, Roy CJ, O'Neil CP, Browning EA, Pittet LA, Altreuter DH, Alexis F, Tonti E, Shi J, Basto PA, et al. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine 2014; 32(24):2882-95; PMID:24593999; http://dx.doi.org/10.1016/j.vaccine.2014.02.027
   PubMed Web of Science ®Google Scholar
• Liu X, Xu Y, Yu T, Clifford C, Liu Y, Yan H, Chang Y. A DNA nanostructure platform for directed assembly of synthetic vaccines. Nano Lett 2012; 12(8):4254-9; PMID:22746330; http://dx.doi.org/10.1021/nl301877k
   PubMed Web of Science ®Google Scholar
• Rudra JS, Mishra S, Chong AS, Mitchell RA, Nardin EH, Nussenzweig V, Collier JH. Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope. Biomaterials 2012; 33(27):6476-84; PMID:22695068; http://dx.doi.org/10.1016/j.biomaterials.2012.05.041
   PubMed Web of Science ®Google Scholar
• Rudra JS, Ding Y, Neelakantan H, Ding C, Appavu R, Stutz S, Snook JD, Chen H, Cunningham KA, Zhou J. Suppression of Cocaine-Evoked Hyperactivity by Self-Adjuvanting and Multivalent Peptide Nanofiber Vaccines. ACS Chem Neurosci 2016; 7(5):546-52; PMID:26926328; http://dx.doi.org/10.1021/acschemneuro.5b00345
   PubMed Web of Science ®Google Scholar
• Stavropoulos P, Papavasiliou FN. Using T. brucei as a biological epitope-display platform to elicit specific antibody responses. J Immunol Methods 2010; 362(1-2):190-4; PMID:20800596; http://dx.doi.org/10.1016/j.jim.2010.08.009
   PubMed Web of Science ®Google Scholar
• Astronomo RD, Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 2010; 9(4):308-24; PMID:20357803; http://dx.doi.org/10.1038/nrd3012
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010; 10(11):787-96; PMID:20948547; http://dx.doi.org/10.1038/nri2868
   PubMed Web of Science ®Google Scholar
• Irvine DJ, Swartz MA, Szeto GL. Engineering synthetic vaccines using cues from natural immunity. Nat Mater 2013; 12(11):978-90; PMID:24150416; http://dx.doi.org/10.1038/nmat3775
   PubMed Web of Science ®Google Scholar
• Hanson MC, Crespo MP, Abraham W, Moynihan KD, Szeto GL, Chen SH, Melo MB, Mueller S, Irvine DJ. Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J Clin Invest 2015; 125(6):2532-46; PMID:25938786; http://dx.doi.org/10.1172/JCI79915
   PubMed Web of Science ®Google Scholar
• Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, Van Egeren DS, Park C, Irvine DJ. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 2014; 507(7493):519-22; PMID:24531764; http://dx.doi.org/10.1038/nature12978
   PubMed Web of Science ®Google Scholar
• de Villiers SH, Cornish KE, Troska AJ, Pravetoni M, Pentel PR. Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine 2013; 31(52):6185-93; PMID:24176492; http://dx.doi.org/10.1016/j.vaccine.2013.10.051
   PubMed Web of Science ®Google Scholar
• Ohia-Nwoko O, Kosten TA, Haile CN. Animal models and the development of vaccines to treat substance use disorders. Int Rev Neurobiol 2016; 126:263-91; PMID:27055616; http://dx.doi.org/10.1016/bs.irn.2016.02.009
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. Vaccines, new opportunities for a new society. Proc Natl Acad Sci U S A 2014; 111(34):12288-93; PMID:25136130; http://dx.doi.org/10.1073/pnas.1402981111
   PubMed Web of Science ®Google Scholar
• Carrera MR, Ashley JA, Hoffman TZ, Isomura S, Wirsching P, Koob GF, Janda KD. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem 2004; 12(3):563-70; PMID:14738965; http://dx.doi.org/10.1016/j.bmc.2003.11.029
   PubMed Web of Science ®Google Scholar
• Keyler DE, Roiko SA, Benlhabib E, LeSage MG, St Peter JV, Stewart S, Fuller S, Le CT, Pentel PR. Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab Dispos 2005; 33(7):1056-61; PMID:15843487; http://dx.doi.org/10.1124/dmd.105.004234
   PubMed Web of Science ®Google Scholar
• Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ, French TL, Thompson TL, Schad VC, Greenstein JL, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996; 2(10):1129-32; PMID:8837612; http://dx.doi.org/10.1038/nm1096-1129
   PubMed Web of Science ®Google Scholar
• Carrera MR, Ashley JA, Zhou B, Wirsching P, Koob GF, Janda KD. Cocaine vaccines: antibody protection against relapse in a rat model. Proc Natl Acad Sci U S A 2000; 97(11):6202-6; PMID:10823960; http://dx.doi.org/10.1073/pnas.97.11.6202
   PubMed Web of Science ®Google Scholar
• Norman AB, Norman MK, Buesing WR, Tabet MR, Tsibulsky VL, Ball WJ. The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. J Pharmacol Exp Ther 2009; 328(3):873-81; PMID:19088302; http://dx.doi.org/10.1124/jpet.108.146407
   PubMed Web of Science ®Google Scholar
• Hardin JS, Wessinger WD, Wenger GR, Proksch JW, Laurenzana EM, Owens SM. A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. J Pharmacol Exp Ther 2002; 302(1):119-26; PMID:12065708; http://dx.doi.org/10.1124/jpet.302.1.119
   PubMed Web of Science ®Google Scholar
• Gentry WB, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, Owens SM. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol 2006; 6(6):968-77; PMID:16644483; http://dx.doi.org/10.1016/j.intimp.2006.01.008
   PubMed Web of Science ®Google Scholar
• Bogen IL, Boix F, Nerem E, Morland J, Andersen JM. A monoclonal antibody specific for 6-monoacetylmorphine reduces acute heroin effects in mice. J Pharmacol Exp Ther 2014; 349(3):568-76; PMID:24700886; http://dx.doi.org/10.1124/jpet.113.212035
   PubMed Web of Science ®Google Scholar
• Kvello AM, Andersen JM, Oiestad EL, Morland J, Bogen IL. The pharmacological effects of a monoclonal antibody against 6-monoacetylmorphine upon heroin induced locomotor activity and pharmacokinetics in mice. J Pharmacol Exp Ther 2016; 358(2):181-9; PMID:27217591; http://dx.doi.org/10.1124/jpet.116.233510
   PubMed Web of Science ®Google Scholar
• Stevens MW, Henry RL, Owens SM, Schutz R, Gentry WB. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. MAbs 2014; 6(6):1649-56; PMID:25484042; http://dx.doi.org/10.4161/19420862.2014.976431
   PubMed Web of Science ®Google Scholar
• Kirley TL, Norman AB. Characterization of a recombinant humanized anti-cocaine monoclonal antibody and its fab fragment. Hum Vaccin Immunother 2015; 11(2):458-67; PMID:25692880; http://dx.doi.org/10.4161/21645515.2014.990856
   PubMed Web of Science ®Google Scholar
• Cohen-Barak O, Wildeman J, van de Wetering J, Hettinga J, Schuilenga-Hut P, Gross A, Clark S, Bassan M, Gilgun-Sherki Y, Mendzelevski B, et al. Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects. J Clin Pharmacol 2015; 55(5):573-83; PMID:25524052; http://dx.doi.org/10.1002/jcph.450
   PubMed Web of Science ®Google Scholar
• Nasser AF, Fudala PJ, Zheng B, Liu Y, Heidbreder C. A randomized, double-blind, placebo-controlled trial of RBP-8000 in cocaine abusers: pharmacokinetic profile of rbp-8000 and cocaine and effects of RBP-8000 on cocaine-induced physiological effects. J Addict Dis 2014; 33(4):289-302; PMID:25299069; http://dx.doi.org/10.1080/10550887.2014.969603
   PubMed Web of Science ®Google Scholar
• Shram MJ, Cohen-Barak O, Chakraborty B, Bassan M, Schoedel KA, Hallak H, Eyal E, Weiss S, Gilgun Y, Sellers EM, et al. Assessment of Pharmacokinetic and Pharmacodynamic Interactions between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users. J Clin Psychopharmacol 2015; 35(4):396-405; PMID:26082975
   PubMed Web of Science ®Google Scholar
• Nanaware-Kharade N, Thakkar S, Gonzalez GA, 3rd, Peterson EC. A Nanotechnology-Based platform for extending the pharmacokinetic and binding properties of anti-methamphetamine antibody fragments. Sci Rep 2015; 5:12060; PMID:26159352; http://dx.doi.org/10.1038/srep12060
   PubMed Web of Science ®Google Scholar
• Wilson PC, Andrews SF. Tools to therapeutically harness the human antibody response. Nat Rev Immunol 2012; 12(10):709-19; PMID:23007571; http://dx.doi.org/10.1038/nri3285
   PubMed Web of Science ®Google Scholar
• Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453(7195):667-71; PMID:18449194; http://dx.doi.org/10.1038/nature06890
   PubMed Web of Science ®Google Scholar
• Corti D, Lanzavecchia A. Efficient methods to isolate human monoclonal antibodies from memory B cells and plasma cells. Microbiol Spectr 2014; 2(5); PMID:26104354; http://dx.doi.org/10.1128/microbiolspec.AID-0018-2014
   PubMedGoogle Scholar
• Beerli RR, Bauer M, Buser RB, Gwerder M, Muntwiler S, Maurer P, Saudan P, Bachmann MF. Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A 2008; 105(38):14336-41; PMID:18812621; http://dx.doi.org/10.1073/pnas.0805942105
   PubMed Web of Science ®Google Scholar
• LeSage MG, Shelley D, Pravetoni M, Pentel PR. Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist. Pharmacol Biochem Behav 2012; 102(1):157-62; PMID:22503967; http://dx.doi.org/10.1016/j.pbb.2012.03.026
   PubMed Web of Science ®Google Scholar
• Cornish KE, Harris AC, LeSage MG, Keyler DE, Burroughs D, Earley C, Pentel PR. Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy. Int Immunopharmacol 2011; 11(11):1809-15; PMID:21802529; http://dx.doi.org/10.1016/j.intimp.2011.07.009
   PubMed Web of Science ®Google Scholar
• Hambuchen MD, Carroll FI, Ruedi-Bettschen D, Hendrickson HP, Hennings LJ, Blough BE, Brieaddy LE, Pidaparthi RR, Owens SM. Combining active immunization with monoclonal antibody therapy to facilitate early initiation of a long-acting anti-methamphetamine antibody response. J Med Chem 2015; 58(11):4665-77; PMID:25973614; http://dx.doi.org/10.1021/acs.jmedchem.5b00220
   PubMed Web of Science ®Google Scholar
• Larrimore KE, Barcus M, Kannan L, Gao Y, Zhan CG, Brimijoin S, Mor T. Plants as a source of butyrylcholinesterase variants designed for enhanced cocaine hydrolase activity. Chem Biol Interact 2013; 203(1):217-20; PMID:23000451; http://dx.doi.org/10.1016/j.cbi.2012.09.004
   PubMed Web of Science ®Google Scholar
• Zheng F, Xue L, Hou S, Liu J, Zhan M, Yang W, Zhan CG. A highly efficient cocaine-detoxifying enzyme obtained by computational design. Nat Commun. 2014; 5:3457; PMID:24643289
   PubMed Web of Science ®Google Scholar
• Fang L, Hou S, Xue L, Zheng F, Zhan CG. Amino-acid mutations to extend the biological half-life of a therapeutically valuable mutant of human butyrylcholinesterase. Chem Biol Interact 2014; 214:18-25; PMID:24582612; http://dx.doi.org/10.1016/j.cbi.2014.02.007
   PubMed Web of Science ®Google Scholar
• Collins GT, Narasimhan D, Cunningham AR, Zaks ME, Nichols J, Ko MC, Sunahara RK, Woods JH. Long-lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats. Neuropsychopharmacol 2012; 37(5):1092-103; http://dx.doi.org/10.1038/npp.2011.226
   PubMed Web of Science ®Google Scholar
• Brimijoin S, Orson F, Kosten TR, Kinsey B, Shen XY, White SJ, Gao Y. Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice. Chem Biol Interact 2013; 203(1):212-6; PMID:22960160; http://dx.doi.org/10.1016/j.cbi.2012.08.015
   PubMed Web of Science ®Google Scholar
• Xue S, Schlosburg JE, Janda KD. A new strategy for smoking cessation: characterization of a bacterial enzyme for the degradation of nicotine. J Am Chem Soc 2015; 137(32):10136-9; PMID:26237398; http://dx.doi.org/10.1021/jacs.5b06605
   PubMed Web of Science ®Google Scholar
• Landry DW, Zhao K, Yang GX, Glickman M, Georgiadis TM. Antibody-catalyzed degradation of cocaine. Science 1993; 259(5103):1899-901; PMID:8456315; http://dx.doi.org/10.1126/science.8456315
   PubMed Web of Science ®Google Scholar
• Xu Y, Hixon MS, Yamamoto N, McAllister LA, Wentworth AD, Wentworth P, Jr, Janda KD. Antibody-catalyzed anaerobic destruction of methamphetamine. Proc Natl Acad Sci U S A 2007; 104(10):3681-6; PMID:17360412; http://dx.doi.org/10.1073/pnas.0611094104
   PubMed Web of Science ®Google Scholar
• Dickerson TJ, Yamamoto N, Janda KD. Antibody-catalyzed oxidative degradation of nicotine using riboflavin. Bioorg Med Chem 2004; 12(18):4981-7; PMID:15336277; http://dx.doi.org/10.1016/j.bmc.2004.07.006
   PubMed Web of Science ®Google Scholar
• Chen X, Xue L, Hou S, Jin Z, Zhang T, Zheng F, Zhan CG. Long-acting cocaine hydrolase for addiction therapy. Proc Natl Acad Sci U S A 2016; 113(2):422-7; PMID:26712009; http://dx.doi.org/10.1073/pnas.1517713113
   PubMed Web of Science ®Google Scholar
• Hicks MJ, Rosenberg JB, De BP, Pagovich OE, Young CN, Qiu JP, Kaminsky SM, Hackett NR, Worgall S, Janda KD, et al. AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation. Sci Transl Med 2012; 4(140):140ra187; http://dx.doi.org/10.1126/scitranslmed.3003611
   Web of Science ®Google Scholar
• Rosenberg JB, Hicks MJ, De BP, Pagovich O, Frenk E, Janda KD, Wee S, Koob GF, Hackett NR, Kaminsky SM, et al. AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior. Hum Gene Ther 2012; 23(5):451-9; PMID:22486244; http://dx.doi.org/10.1089/hum.2011.178
   PubMed Web of Science ®Google Scholar
• Carroll ME, Zlebnik NE, Anker JJ, Kosten TR, Orson FM, Shen X, Kinsey B, Parks RJ, Gao Y, Brimijoin S. Combined cocaine hydrolase gene transfer and anti-cocaine vaccine synergistically block cocaine-induced locomotion. PLoS One 2012; 7(8):e43536; PMID:22912888; http://dx.doi.org/10.1371/journal.pone.0043536
   PubMed Web of Science ®Google Scholar
• Smethells JR, Swalve N, Brimijoin S, Gao Y, Parks RJ, Greer A, Carroll ME. Long-Term blockade of cocaine self-administration and locomotor activation in rats by an adenoviral vector-delivered cocaine hydrolase. J Pharmacol Exp Ther 2016; 357(2):375-81; PMID:26968195; http://dx.doi.org/10.1124/jpet.116.232504
   PubMed Web of Science ®Google Scholar
• Murthy V, Gao Y, Geng L, LeBrasseur NK, White TA, Parks RJ, Brimijoin S. Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice. Vaccine 2014; 32(33):4155-62; PMID:24892251; http://dx.doi.org/10.1016/j.vaccine.2014.05.067
   PubMed Web of Science ®Google Scholar
• Murthy V, Gao Y, Geng L, LeBrasseur N, White T, Brimijoin S. Preclinical studies on neurobehavioral and neuromuscular effects of cocaine hydrolase gene therapy in mice. J Mol Neurosci 2014; 53(3):409-16; PMID:24085526; http://dx.doi.org/10.1007/s12031-013-0130-5
   PubMed Web of Science ®Google Scholar
• Murthy V, Reyes S, Geng L, Gao Y, Brimijoin S. Cocaine Hydrolase Gene Transfer Demonstrates Cardiac Safety and Efficacy against Cocaine-Induced QT Prolongation in Mice. J Pharmacol Exp Ther 2016; 356(3):720-5; PMID:26669428; http://dx.doi.org/10.1124/jpet.115.228825
   PubMed Web of Science ®Google Scholar
• Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, de Vos A, Horwith G, Pentel PR. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005; 78(5):456-67; PMID:16321612; http://dx.doi.org/10.1016/j.clpt.2005.08.007
   PubMed Web of Science ®Google Scholar
• Hoogsteder PH, Kotz D, van Spiegel PI, Viechtbauer W, van Schayck OC. Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. Addiction 2014; 109(8):1252-9; PMID:24894625; http://dx.doi.org/10.1111/add.12573
   PubMed Web of Science ®Google Scholar
• Hoogsteder PH, Kotz D, van Spiegel PI, Viechtbauer W, Brauer R, Kessler PD, Kalnik MW, Fahim RE, van Schayck OC. The efficacy and safety of a nicotine conjugate vaccine (NicVAX(R)) or placebo co-administered with varenicline (Champix(R)) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial. BMC Public Health 2012; 12:1052; PMID:23216646; http://dx.doi.org/10.1186/1471-2458-12-1052
   PubMed Web of Science ®Google Scholar
• Esterlis I, Hannestad JO, Perkins E, Bois F, D'Souza DC, Tyndale RF, Seibyl JP, Hatsukami DM, Cosgrove KP, O'Malley SS. Effect of a nicotine vaccine on nicotine binding to beta2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. Am J Psychiatry 2013; 170(4):399-407; PMID:23429725; http://dx.doi.org/10.1176/appi.ajp.2012.12060793
   PubMed Web of Science ®Google Scholar
• Tonstad S, Heggen E, Giljam H, Lagerback PA, Tonnesen P, Wikingsson LD, Lindblom N, de Villiers S, Svensson TH, Fagerstrom KO. Niccine(R), a nicotine vaccine, for relapse prevention: A Phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tob Res 2013; 15(9):1492-501; PMID:23471101; http://dx.doi.org/10.1093/ntr/ntt003
   PubMed Web of Science ®Google Scholar
• Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J, Jack L, Fox B. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002; 20(7-8):1196-204; PMID:11803082; http://dx.doi.org/10.1016/S0264-410X(01)00425-X
   PubMed Web of Science ®Google Scholar
• Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 2010; 67(1):59-65; PMID:19846066; http://dx.doi.org/10.1016/j.biopsych.2009.08.031
   PubMed Web of Science ®Google Scholar